Praxis Precision’s relutrigine reduces seizures in rare epileptic disorders in phase 2 clinical trials
Relutrigine resulted in a 46% reduction in seizures and seizure freedom in 30% of patients. Patients also experienced meaningful improvements ...
Tag: relutrigine
